within Pharmacolibrary.Drugs.ATC.A;

model A02BX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A02BX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Zolimidine is a substituted benzamidine formerly used as a gastric acid secretion inhibitor in the treatment of peptic ulcers and related gastrointestinal disorders. It is not currently approved or widely used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult, healthy subjects for oral administration as no published studies reporting human PK parameters were found.</p><h4>References</h4><ol><li><p>Schraven, E, &amp; Trottnow, D (1976). [The pharmacokinetics of 14C-zolimidine in rats]. <i>Arzneimittel-Forschung</i> 26(2) 213–218. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/947201/\">https://pubmed.ncbi.nlm.nih.gov/947201</a></p></li><li><p>Almirante, L, et al., &amp; Cattaneo, R (1974). Metabolic fate of Zolimidine. I. Studies in rats with the 14-C-labelled molecule. <i>Il Farmaco; edizione scientifica</i> 29(11) 841–847. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4442572/\">https://pubmed.ncbi.nlm.nih.gov/4442572</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A02BX10;
